AbbVie: Upadacitinib Achieved Clinical Remission at One Year in Crohn's Disease
May 11 2022 - 9:38AM
Dow Jones News
By Michael Dabaie
AbbVie said epadacitinib achieved clinical remission and
endoscopic response at one year in a Phase 3 maintenance study in
patients with Crohn's disease.
The company said it had positive topline results from U-ENDURE,
its Phase 3 maintenance study evaluating upadacitinib in adult
patients with moderate to severe Crohn's disease who had an
inadequate response or were intolerant to a conventional or
biologic therapy.
The results showed that more patients treated with either dose
of upadacitinib--15 mg or 30 mg once daily--achieved the co-primary
objective of endoscopic response and clinical remission, and the
secondary endpoint of endoscopic remission, at one year compared to
placebo.
Use of upadacitinib in Crohn's disease hasn't been evaluated by
health authorities. Results from the U-ENDURE maintenance study, in
addition to results from the U-EXCEED and U-EXCEL induction
studies, will be included in future regulatory submissions, AbbVie
said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 11, 2022 09:23 ET (13:23 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024
